In the last three months, 15 analysts have published ratings on Doximity DOCS, offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 10 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 5 | 0 | 0 |
| 3M Ago | 0 | 3 | 2 | 1 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Doximity, presenting an average target of $55.13, a high estimate of $75.00, and a low estimate of $33.00. Observing a 38.76% increase, the current average has risen from the previous average price target of $39.73.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of Doximity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stan Berenshteyn | Wells Fargo | Raises | Equal-Weight | $43.00 | $41.00 |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $65.00 | $70.00 |
| Allen Lutz | B of A Securities | Raises | Neutral | $57.00 | $54.00 |
| Jeff Garro | Stephens & Co. | Announces | Equal-Weight | $55.00 | - |
| Steven Valiquette | Mizuho | Announces | Neutral | $55.00 | - |
| Anne Samuel | JP Morgan | Raises | Neutral | $48.00 | $30.00 |
| David Roman | Goldman Sachs | Announces | Neutral | $58.00 | - |
| Jailendra Singh | Truist Securities | Raises | Hold | $49.00 | $35.00 |
| Ricky Goldwasser | Morgan Stanley | Raises | Equal-Weight | $53.00 | $33.00 |
| Richard Close | Canaccord Genuity | Raises | Hold | $60.00 | $40.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $75.00 | $52.00 |
| Brian Peterson | Raymond James | Raises | Outperform | $65.00 | $37.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Equal-Weight | $41.00 | $19.00 |
| Scott Schoenhaus | Keybanc | Announces | Overweight | $70.00 | - |
| Ricky Goldwasser | Morgan Stanley | Raises | Underweight | $33.00 | $26.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Doximity. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Doximity compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Doximity's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Doximity's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Doximity analyst ratings.
Discovering Doximity: A Closer Look
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Doximity's Financial Performance
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Doximity's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 20.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 32.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of 4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Doximity's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
